Biotech Values

[DewDiligence]

GH IPOs 14.38M* shares @$19.00:

https://globenewswire.com/news-release/2018/10/03/1601106/0/en/Guardant-Health-Announces-Pricing-of-Initial-Public-Offering.html

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics… In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.

*Assuming exercise of underwriter’s option.